These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 11274240)
1. A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. Donadio JV; Larson TS; Bergstralh EJ; Grande JP J Am Soc Nephrol; 2001 Apr; 12(4):791-799. PubMed ID: 11274240 [TBL] [Abstract][Full Text] [Related]
2. Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy? Donadio JV; Bergstralh EJ; Bibus DM; Grande JP Clin J Am Soc Nephrol; 2006 Sep; 1(5):933-9. PubMed ID: 17699310 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent. Hogg RJ; Fitzgibbons L; Atkins C; Nardelli N; Bay RC; Clin J Am Soc Nephrol; 2006 Nov; 1(6):1167-72. PubMed ID: 17699343 [TBL] [Abstract][Full Text] [Related]
4. Treatment of severe IgA nephropathy with omega-3 fatty acids: the effect of a "very low dose" regimen. Alexopoulos E; Stangou M; Pantzaki A; Kirmizis D; Memmos D Ren Fail; 2004 Jul; 26(4):453-9. PubMed ID: 15462115 [TBL] [Abstract][Full Text] [Related]
5. Effect of fish oil on oxidative stress, lipid profile and renal function in IgA nephropathy. Parinyasiri U; Ong-Ajyooth L; Parichatikanond P; Ong-Ajyooth S; Liammongkolkul S; Kanyog S J Med Assoc Thai; 2004 Feb; 87(2):143-9. PubMed ID: 15061297 [TBL] [Abstract][Full Text] [Related]
6. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Ethyl-Ester Omega-3 Fatty Acid in Taiwanese Hypertriglyceridemic Patients. Su TC; Hwang JJ; Huang KC; Chiang FT; Chien KL; Wang KY; Charng MJ; Tsai WC; Lin LY; Vige R; Olivar JE; Tseng CD J Atheroscler Thromb; 2017 Mar; 24(3):275-289. PubMed ID: 27600795 [TBL] [Abstract][Full Text] [Related]
7. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. McKenney JM; Sica D Pharmacotherapy; 2007 May; 27(5):715-28. PubMed ID: 17461707 [TBL] [Abstract][Full Text] [Related]
8. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Bays H Am J Cardiol; 2006 Aug; 98(4A):71i-76i. PubMed ID: 16919519 [TBL] [Abstract][Full Text] [Related]
9. Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia. Rupp H Adv Ther; 2009 Jul; 26(7):675-90. PubMed ID: 19629408 [TBL] [Abstract][Full Text] [Related]
10. Risk stratification by the "EPA+DHA level" and the "EPA/AA ratio" focus on anti-inflammatory and antiarrhythmogenic effects of long-chain omega-3 fatty acids. Rupp H; Wagner D; Rupp T; Schulte LM; Maisch B Herz; 2004 Nov; 29(7):673-85. PubMed ID: 15580322 [TBL] [Abstract][Full Text] [Related]
12. The Renoprotective Effects of Docosahexaenoic Acid as an Add-on Therapy in Patients Receiving Eicosapentaenoic Acid as Treatment for IgA Nephropathy: A Pilot Uncontrolled Trial. Moriyama T; Kumon S; Kamiyama T; Karasawa K; Uchida K; Nitta K Intern Med; 2018 Jan; 57(2):173-179. PubMed ID: 29093399 [TBL] [Abstract][Full Text] [Related]
13. n-3 fatty acids and cardiovascular events after myocardial infarction. Kromhout D; Giltay EJ; Geleijnse JM; N Engl J Med; 2010 Nov; 363(21):2015-26. PubMed ID: 20929341 [TBL] [Abstract][Full Text] [Related]
14. Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. Hogg RJ; Lee J; Nardelli N; Julian BA; Cattran D; Waldo B; Wyatt R; Jennette JC; Sibley R; Hyland K; Fitzgibbons L; Hirschman G; Donadio JV; Holub BJ; Clin J Am Soc Nephrol; 2006 May; 1(3):467-74. PubMed ID: 17699247 [TBL] [Abstract][Full Text] [Related]
15. Effect of Vitamin D and Omega-3 Fatty Acid Supplementation on Kidney Function in Patients With Type 2 Diabetes: A Randomized Clinical Trial. de Boer IH; Zelnick LR; Ruzinski J; Friedenberg G; Duszlak J; Bubes VY; Hoofnagle AN; Thadhani R; Glynn RJ; Buring JE; Sesso HD; Manson JE JAMA; 2019 Nov; 322(19):1899-1909. PubMed ID: 31703120 [TBL] [Abstract][Full Text] [Related]
16. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. Donadio JV; Bergstralh EJ; Offord KP; Spencer DC; Holley KE N Engl J Med; 1994 Nov; 331(18):1194-9. PubMed ID: 7935657 [TBL] [Abstract][Full Text] [Related]
17. Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study. Dunbar RL; Gaudet D; Davidson M; Rensfeldt M; Yang H; Nilsson C; Kvarnström M; Oscarsson J Lipids Health Dis; 2020 May; 19(1):117. PubMed ID: 32473640 [TBL] [Abstract][Full Text] [Related]
18. Omacor effects on serum lipids and clinical outcome. Ito MK; Marrs J; Williams C Am J Cardiol; 2007 Jan; 99(1):145. PubMed ID: 17196478 [No Abstract] [Full Text] [Related]
19. Omacor and omega-3 fatty acids for treatment of coronary artery disease and the pleiotropic effects. Kar S Am J Ther; 2014; 21(1):56-66. PubMed ID: 21975796 [TBL] [Abstract][Full Text] [Related]
20. Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Irish A; Dogra G; Mori T; Beller E; Heritier S; Hawley C; Kerr P; Robertson A; Rosman J; Paul-Brent PA; Starfield M; Polkinghorne K; Cass A BMC Nephrol; 2009 Jan; 10():1. PubMed ID: 19159453 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]